Received Mar 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Tiredness; lower back pain; frontal discomfort; changes in her feces that look like constipation; Painful urination; This non-serious case was reported by a consumer via call center representative and described the occurrence of tiredness in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included levothyroxine sodium (Synthroid) and lisdexamfetamine mesilate (Vyvanse). In MAR-2026, the patient received the 1st dose of Shingrix. In MAR-2026, less than an hour after receiving Shingrix, the patient experienced tiredness (Verbatim: Tiredness), low back pain (Verbatim: lower back pain), head discomfort (Verbatim: frontal discomfort), abnormal stools (Verbatim: changes in her feces that look like constipation) and painful urination (Verbatim: Painful urination). The outcome of the tiredness, low back pain, head discomfort, abnormal stools and painful urination were unknown. It was unknown if the reporter considered the tiredness, low back pain, head discomfort, abnormal stools and painful urination to be related to Shingrix. It was unknown if the company considered the tiredness, low back pain, head discomfort, abnormal stools and painful urination to be related to Shingrix. Additional Information: GSK Receipt Date: 11-MAR-2026 The batch number was not provided, and we are unable to contact the reporter.
SYNTHROID; VYVANSE